[HTML][HTML] Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy
TS Uldrick, KM Wyvill, P Kumar… - Journal of clinical …, 2012 - ncbi.nlm.nih.gov
TS Uldrick, KM Wyvill, P Kumar, D O'Mahony, W Bernstein, K Aleman, MN Polizzotto…
Journal of clinical oncology, 2012•ncbi.nlm.nih.govPurpose Alternatives to cytotoxic agents are desirable for patients with HIV-associated
Kaposi's sarcoma (KS). Vascular endothelial growth factor-A (VEGF-A) contributes to KS
pathogenesis. We evaluated the humanized anti–VEGF-A monoclonal antibody,
bevacizumab, in patients with HIV-KS.
Kaposi's sarcoma (KS). Vascular endothelial growth factor-A (VEGF-A) contributes to KS
pathogenesis. We evaluated the humanized anti–VEGF-A monoclonal antibody,
bevacizumab, in patients with HIV-KS.
Abstract
Purpose
Alternatives to cytotoxic agents are desirable for patients with HIV-associated Kaposi's sarcoma (KS). Vascular endothelial growth factor-A (VEGF-A) contributes to KS pathogenesis. We evaluated the humanized anti–VEGF-A monoclonal antibody, bevacizumab, in patients with HIV-KS.
ncbi.nlm.nih.gov